SES Logo

SYSTEMIC ENZYME SUPPORT.org

 

Diabetes

We know that Wobenzym can increase levels of C-peptide in autoimmune mediated diabetes, such as type 1 diabetes. In addition to showing much insulin the pancreas can still make, C-peptide decreases the progression so the common complications of diabetes, including the diabetic nephropathy.
We also note that systemic enzymes can decrease the formation of “advanced glycation end products” (AGEs), which are associated with diabetic nephropathy and other complications of diabetes.
IN addition, abnormal cytokines levels are normalized, including transforming growth factor beta-1 (TGF-b1), and interleukin 6.
What we have come to realize, is that the complications of diabetes are strongly mediated by the immune system. We see that controlling blood sugar with insulin is not enough to prevent complications such as diabetic nephropathy. The abnormal cytokine levels that occur with diabetes can safely and effectively be normalized with Wobenzym.
                                    From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND
                                    Read the special section: KIDNEY AND BLADDER CONDITIONS & WOBENZYM®

What the literature says about Systemic Enzyme Support and:

Diabetes Mellitus

Regular intake of Wobenzym® may prevent late complications in diabetes mellitus. 

Dzivite I.,1 Sochnevs A.,2 Stauder G.,3 Zeibarts M.,4 Lauga U.,4 Ansbergs J.5. Regular intake of Wobenzym® may prevent late complications in diabetes mellitus. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 143-148- ISSN 0255-9625 218 K/375 (19-05-3) 1. Children’s and Teenagers’ Endocrinology Center, Bernu Kliniska University Slimnica, Pediatric University Hospital, Riga, Latvia 2. Institute of Immunology, Riga Stradins University and Latvian Medical Academy, Riga, Latvia. 3. Riga Stradins University and Latvian Medical Academy, Riga, Latvia. 4. MUCOS-Balt Ltd., Riga, Latvia. 

Summary: In this observational study, the results of a 12-month treatment of two groups of children, aged 4-18 years, with newly diagnosed type 1 diabetes were compared. Half of the patients received insulin preparation only, while the other half was treated with the combination of a similar insulin preparation and Wobenzym®. At the start of therapy, the mean values of all laboratory indices were similar in both groups of children.
A difference between mean HbA1c levels in both groups was observed at the first follow-up (p = 0.0179). During treatment, further differences became highly significant in favor of the enzyme group (p <0.0001). After 12 months, higher levels of C-peptide were found in children treated with Wobenzym® (p = 0.0012). At the start of therapy there were no differences between the groups of children in the dosage of insulin used. However, from the first follow-up visit, greater amounts of insulin were used in the control group.
The difference between circulating immune complexes (CIC) levels at the start and end of therapy was also significant in favor of the enzyme group (p = 0.0018). Enzyme therapy caused no undesirable adverse effects. Based on the results obtained, Wobenzym® can be assumed to decrease the activity of the inflammatory process and support a restitution of pancreatic b-cells. This may explain the improved metabolic compensation found in patients who received Wobenzym®.
We suggest that regular intake of Wobenzym® together with individually adjusted insulin therapy can prevent the development of late pathological outcomes in diabetes.
Poster Reference Number 17. 

Protease Treatment Delays Diabetes Onset in Diabetes-prone Nonobese Diabetic (NOD) Mice.  

Wiest-Ladenburger U.,1 Richter W.,1 Moeller P.,2 Boehm B. O.1 Protease Treatment Delays Diabetes Onset in Diabetes-prone Nonobese Diabetic (NOD) Mice. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 75-78 - ISSN 0255-9625. Inter. Journal of  Tissue Reactions 1997, Vol. XIX, No. 1/2,  abstract 108, pp. 89 - ISSN 0250-0868 SO 112 (4-12-2) (19-04-2) 1 Abteilung Innere Medizin I, Universität Ulm, Ulm, Germany, 2 Institut für Pathologie, Universität Ulm, Ulm, Germany. 7th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, May 19-21, Geneva, Switzerland  

Summary: It has recently been demonstrated that proteolytic enzyme treatment modulates certain immune-mediated diseases. We have, therefore, studied the effect of administration of a protease mixture in the NOD mouse, an elegant animal model for autoimmune insulin-dependent diabetes mellitus (IDDM). Female NOD mice were fed proteolytic enzymes from age 6 weeks to 10 weeks, within the subclinical phase of IDDM. Once a week animals received intragastrically 1 mg Phlogenzym® (n=10 mice) or 0.5 mg Phlogenzym® (n=10) in 0.5 ml saline or saline only (n=10).
Mice were followed for development of IDDM up to week 23. At week 21, all control animals were diabetic, whereas 25% of the treated mice were still normoglycemic at the end of the observation period. No significant appearance of autoantibodies against either isoform of the important islet cell antigen glutamic acid decarboxylase (GAD), GAD65 and GAD67, was observed in the mouse sera as determined by a highly sensitive radioimmunoassay. The histopathological examination of pancreatic islets showed signs of insulitis in all mice with a tendency of milder insulitis in the protease-treated groups.